Status:
RECRUITING
Randomized Controlled Trial Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Obesity
Weight Loss
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Eligibility Criteria
Inclusion
- 6 months after metabolic surgery; 18 years ≤ age ≤ 55 years; Body Mass Index (BMI) ≥ 28 kg/m\^2
Exclusion
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07163650
Start Date
September 1 2025
End Date
February 28 2027
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China